Syros Pharmaceuticals, Inc. - common stock (SYRS): Price and Financial Metrics
GET POWR RATINGS... FREE!
SYRS POWR Grades
- SYRS scores best on the Sentiment dimension, with a Sentiment rank ahead of 73.17% of US stocks.
- The strongest trend for SYRS is in Momentum, which has been heading down over the past 179 days.
- SYRS ranks lowest in Momentum; there it ranks in the 14th percentile.
SYRS Stock Summary
- Of note is the ratio of Syros Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; merely 7.3% of US stocks have a lower such ratio.
- In terms of volatility of its share price, SYRS is more volatile than 93.03% of stocks we're observing.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SYRS comes in at -98.82% -- higher than that of only 3.95% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Syros Pharmaceuticals Inc are ALPN, ABUS, CLLS, MGNX, and IMGN.
- SYRS's SEC filings can be seen here. And to visit Syros Pharmaceuticals Inc's official web site, go to www.syros.com.
SYRS Valuation Summary
- In comparison to the median Healthcare stock, SYRS's price/sales ratio is 342.11% higher, now standing at 16.8.
- SYRS's EV/EBIT ratio has moved up 7 over the prior 63 months.
- Over the past 63 months, SYRS's price/sales ratio has gone down 1286.4.
Below are key valuation metrics over time for SYRS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SYRS | 2021-08-31 | 16.8 | 2.5 | -3.8 | -2.8 |
| SYRS | 2021-08-30 | 16.6 | 2.5 | -3.7 | -2.7 |
| SYRS | 2021-08-27 | 16.4 | 2.5 | -3.7 | -2.7 |
| SYRS | 2021-08-26 | 15.6 | 2.3 | -3.5 | -2.5 |
| SYRS | 2021-08-25 | 15.1 | 2.3 | -3.4 | -2.4 |
| SYRS | 2021-08-24 | 15.0 | 2.3 | -3.4 | -2.4 |
SYRS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SYRS has a Quality Grade of C, ranking ahead of 31.76% of graded US stocks.
- SYRS's asset turnover comes in at 0.093 -- ranking 271st of 682 Pharmaceutical Products stocks.
- ONVO, OPK, and ICPT are the stocks whose asset turnover ratios are most correlated with SYRS.
The table below shows SYRS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.093 | 1 | -1.040 |
| 2021-03-31 | 0.093 | 1 | -1.148 |
| 2020-12-31 | 0.092 | 1 | -1.221 |
| 2020-09-30 | 0.067 | 1 | -0.971 |
| 2020-06-30 | 0.044 | 1 | -0.838 |
| 2020-03-31 | 0.026 | 1 | -0.889 |
SYRS Price Target
For more insight on analysts targets of SYRS, see our SYRS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $17.29 | Average Broker Recommendation | 1.44 (Moderate Buy) |
SYRS Stock Price Chart Interactive Chart >
SYRS Price/Volume Stats
| Current price | $0.78 | 52-week high | $7.03 |
| Prev. close | $0.77 | 52-week low | $0.72 |
| Day low | $0.72 | Volume | 730,678 |
| Day high | $0.82 | Avg. volume | 712,093 |
| 50-day MA | $1.03 | Dividend yield | N/A |
| 200-day MA | $3.02 | Market Cap | 48.26M |
Syros Pharmaceuticals, Inc. - common stock (SYRS) Company Bio
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company was founded in 2011 and is based in Cambridge, Massachusetts.
Latest SYRS News From Around the Web
Below are the latest news stories about Syros Pharmaceuticals Inc that investors may wish to consider to help them evaluate SYRS as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayGood morning, trader! |
Syros rises 13% as tamibarotene gets FDA orphan drug status for myelodysplastic syndromeThe U.S. Food and Drug Administration granted orphan drug designation to Syros Pharmaceuticals' (NASDAQ:SYRS) tamibarotene to treat myelodysplastic syndrome (MDS). Tamibarotene is currently being evaluated in combination with azacitidine in a phase 3 trial, dubbed SELECT-MDS-1, to treat RARA-positive patients with newly diagnosed higher-risk MDS (HR-MDS). The FDA grants orphan status to... |
Syros Receives FDA Orphan Drug Designation for Tamibarotene for the Treatment of MDSCAMBRIDGE, Mass., February 02, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to tamibarotene for the treatment of myelodysplastic syndrome (MDS). Tamibarotene, an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist, is currently being evaluated in combination with azacitidine in the SELECT-MDS- |
Syros Announces Clinical Updates and 2022 Goals to Support its Advancement to a Fully Integrated Biopharmaceutical CompanyCAMBRIDGE, Mass., January 10, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today provided an update on its clinical development programs and outlined its strategic priorities and upcoming expected milestones. |
Here's Why Syros Pharmaceuticals (NASDAQ:SYRS) Can Manage Its Debt Despite Losing MoneySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously... |
SYRS Price Returns
| 1-mo | N/A |
| 3-mo | -50.32% |
| 6-mo | -80.30% |
| 1-year | -85.28% |
| 3-year | -88.39% |
| 5-year | -95.11% |
| YTD | -76.07% |
| 2021 | -69.95% |
| 2020 | 57.02% |
| 2019 | 24.06% |
| 2018 | -42.75% |
| 2017 | -19.98% |
Continue Researching SYRS
Want to see what other sources are saying about Syros Pharmaceuticals Inc's financials and stock price? Try the links below:Syros Pharmaceuticals Inc (SYRS) Stock Price | Nasdaq
Syros Pharmaceuticals Inc (SYRS) Stock Quote, History and News - Yahoo Finance
Syros Pharmaceuticals Inc (SYRS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...